Associate Professor Nick Pavlakis

Medical Oncologist, Associate Professor
Medicine, Northern Clinical School

Telephone +61 2 9926 5020

Map

Keywords

Cancer

Selected grants

2013

  • Improving patient outcomes for patients with Gastrointestinal (GI) cancer through clinical trials research: An application on behalf of the Australasian Gastro-Intestinal Trials Group (AGITG); Goldstein D, Simes R, Abdi E, Ackland S, Pavlakis N, Shannon J; Cancer Institute New South Wales/Cooperative Clinical Trial (CCT) Grants.
  • Development and operational support for the Australasian Lung Cancer Trials Group (ALTG) through the NHMRC Clinical Trial Centre: A NSW-led initiative; Pavlakis N, Boyer M, Stockler M, Dhillon H, Links M, Brown C, Lewis C, Stubbin I; Cancer Institute New South Wales/Cooperative Clinical Trial (CCT) Grants.

2012

  • Bill Walsh LungCancer Res Fund; Pavlakis N; Bill Walsh Lung Cancer Research Fund/Research Donation.

2008

  • Phase III trial of the anti-angiogenic agent Thalidomide in pts with malignant pleural mesothelioma; Pavlakis N; University of Sydney/Bridging Support.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Stordal, B., Pavlakis, N., Davey, R. (2009). A systematic alalysis of oxaliplatin or paclitaxel salvage chemotherapy. In Andrea Bonetti, Roberto Leone,Franco M Muggia, Stephen B Howell (Eds.), Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications, (pp. 225-230). US: Humana Press.
  • Nowak, A., Feigen, M., Pavlakis, N. (2008). Clinical trials in mesothelioma: Australasia? In A Baldi (Eds.), Mesothelioma from Bench Side to Clinic, (pp. 501-519). United States: Nova Science Publishers.
  • Pavlakis, N., Vogelzang, N. (2005). Second-line chemotherapy. In Harvey I Pass, Nicholas J Vogelzang, Michele Carbone (Eds.), Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies, (pp. 607-615). United States of America: Springer.

Journals

  • Wang, F., Gill, A., Neale, M., Puttaswamy, V., Gananadha, S., Pavlakis, N., Clarke, S., Hugh, T., Samra, J. (2014). Adverse tumor biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma. Annals of Surgical Oncology, 21(6), 1937-1947. [More Information]
  • Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer, 110(10), 2462-2471. [More Information]
  • Hudson, A., Weir, C., Moon, E., Harvie, R., Klebe, S., Clarke, S., Pavlakis, N., Howell, V. (2014). Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. Scientific Reports, 4, 6152. [More Information]
  • Cooper, W., Fox, S., O'Toole, S., Morey, A., Frances, G., Pavlakis, N., OBrien, K., Dettrick, A., Leong, T., et al (2014). National Working Group Meeting on ALK diagnostics in lung cancer. Asia-Pacific Journal of Clinical Oncology, 12(SUPPL. 2), 11-17. [More Information]
  • Paik, J., Toon, C., Benn, D., High, H., Hasovitz, C., Pavlakis, N., Clifton-Bligh, R., Gill, A. (2014). Renal Carcinoma Associated With Succinate Dehydrogenase B Mutation: A New and Unique Subtype of Renal Carcinoma. Journal of Clinical Oncology, 32(6), e10-e13. [More Information]
  • Weir, C., Hudson, A., Moon, E., Ross, A., Alexander, M., Peters, L., Langova, V., Clarke, S., Pavlakis, N., Davey, R., Howell, V. (2014). Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines. Cancer Immunology Research, 2(5), 469-479. [More Information]
  • Segelov, E., Chan, D., Shapiro, J., Price, T., Karapetis, C., Tebbutt, N., Pavlakis, N. (2014). The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. British Journal of Cancer, 111(6), 1122-1131. [More Information]
  • Nowak, A., Brown, C., Millward, M., Creaney, J., Byrne, M., Hughes, B., Kremmidiotis, G., Bibby, D., Leske, A., Mitchell, P., Pavlakis, N., Stockler, M., et al (2013). A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer, 81(3), 422-427. [More Information]
  • Vickers, M., Karapetis, C., Tu, D., O'Callaghan, C., Price, T., Tebbutt, N., van Hazel, G., Shapiro, J., Pavlakis, N., Gibbs, P., Simes, R., et al (2013). Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Annals of Oncology, 24(4), 953-960. [More Information]
  • Price, T., Segelov, E., Burge, M., Haller, D., Ackland, S., Tebbutt, N., Karapetis, C., Pavlakis, N., Sobrero, A., Cunningham, D., et al (2013). Current opinion on optimal treatment for colorectal cancer. Expert Review of Anticancer Therapy, 13(5), 597-611. [More Information]
  • Tebbutt, N., Parry, M., Zannino, D., Strickland, A., van Hazel, G., Pavlakis, N., Ganju, V., Mellor, D., Dobrovic, A., Gebski, V. (2013). Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. British Journal of Cancer, 108(4), 771-774. [More Information]
  • Hasovits, C., Pavlakis, N. (2013). EGFR-Targeted therapy and resistance. Cancer Forum, 37(2), 166-170.
  • Kao, S., Vardy, J., Harvie, R., Chatfield, M., van Zandwijk, N., Clarke, S., Pavlakis, N. (2013). Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Supportive Care in Cancer, 21(3), 697-705. [More Information]
  • Pavlakis, N., Solomon, B. (2013). Lung cancer beyond 2013: Many different diseases. Cancer Forum, 37(2), 143-145.
  • Clarke, S., Karapetis, C., Gibbs, P., Pavlakis, N., Desai, J., Michael, M., Tebbutt, N., Price, T., Tabernero, J. (2013). Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors. Critical Reviews in Oncology / Hematology (online), 85(2), 121-135. [More Information]
  • Hasovits, C., Pavlakis, N., Howell, V., Gill, A., Clarke, S. (2013). Resistance to EGFR targeted antibodies - expansion of clones present from the start of treatment. The more things change, the more they stay the same (Plus ca change, plus ca ne change pas!). Translational Gastrointestinal Cancer, 28(1), 44-46. [More Information]
  • Buikhuisen, W., Burgers, J., Vincent, A., Korse, C., van Klaveren, R., Schramel, F., Pavlakis, N., Nowak, A., Custers, F., Schouwink, J., et al (2013). Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology, 14(6), 543-551. [More Information]
  • Cummins, M., Pavlakis, N. (2013). The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events. Therapeutic Advances in Medical Oncology, 5(5), 286-300.
  • Kao, S., Vardy, J., Chatfield, M., Corte, P., Pavlakis, N., Clarke, C., van Zandwijk, N., Clarke, S. (2013). Validation of Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Analysis of Data from Patients Seeking Compensation from the New South Wales Dust Diseases Board. Clinical Lung Cancer, 14(1), 70-77. [More Information]
  • Michael, M., Pavlakis, N., Clingan, P., de Boer, R., Johnston, M., Clarke, S. (2012). A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer. Oncology reports, 28(3), 763-767. [More Information]
  • Wong, M., Stockler, M., Pavlakis, N. (2012). Bisphosphonates and other bone agents for breast cancer (Review). The Cochrane Library Chichester UK: John Wiley and Sons Ltd, 2, 1-136. [More Information]
  • Weickhardt, A., Price, T., Chong, G., Gebski, V., Pavlakis, N., Johns, T., Azad, A., Skrinos, E., Fluck, K., Dobrovic, A., et al (2012). Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. Journal of Clinical Oncology, 30(13), 1505-1512. [More Information]
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Beale, P., Pavlakis, N., Lee, M., Rosenthal, D., Larkey, L., Vardy, J. (2012). Effect of Medical Qigong on Cognitive function, Quality of Life and a Biomarker of Inflammation in Cancer Patients: A Randomized Controlled Trial. Supportive Care in Cancer, 20(6), 1235-1242. [More Information]
  • Boyer, M., Horwood, K., Pavlakis, N., de Souza, P., Millward, M., Stein, B., Johnston, M., Abell, F., Rischin, D. (2012). Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study. Asia-Pacific Journal of Clinical Oncology, 8(3), 248-254. [More Information]
  • Price, T., Shapiro, J., Segelov, E., Karapetis, C., Pavlakis, N., Van Cutsem, E., Shah, M., Kang, Y., Tebbutt, N. (2012). Management of advanced gastric cancer. Expert Review of Gastroenterology and Hepatology, 6(2), 199-209. [More Information]
  • Biankin, A., Waddell, N., Kassahn, K., Gingras, M., Muthuswamy, L., Johns, A., Miller, D., Wilson, P., Patch, A., Wu, J., Gill, A., Kench, J., Pavlakis, N., Lam, V., Richardson, A., Samra, J., et al (2012). Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 491(7424), 399-405. [More Information]
  • Bester, L., Meteling, B., Pocock, N., Pavlakis, N., Chua, T., Saxena, A., Morris, D. (2012). Radioembolization versus Standard Care of Hepatic Metastases: Comparative Retrospective Cohort Study of Survival Outcomes and Adverse Events in Salvage Patients. Journal of Vascular and Interventional Radiology, 23(1), 96-105. [More Information]
  • Kao, S., Harvie, R., Paturi, F., Taylor, R., Davey, R., Abraham, R., Clarke, S., Marx, G., Cullen, M., Kerestes, Z., Pavlakis, N. (2012). The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer, 75(2), 248-254. [More Information]
  • Paech, D., Weston, A., Pavlakis, N., Gill, A., Rajan, N., Barraclough, H., Fitzgerald, B., Van Kooten, M. (2011). A Systematic Review of the Interobserver Variability for Histology in the Differentiation between Squamous and Nonsquamos Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 6(1), 55-63. [More Information]
  • Asmis, T., Powell, E., Karapetis, C., Jonker, D., Tu, D., Jeffery, M., Pavlakis, N., Gibbs, P., Zhu, L., Dueck, D., et al (2011). Comorbidity, age and overall survival in cetuximabtreated patients with advanced colorectal cancer (ACRC)-results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Annals of Oncology, 22, 118-126. [More Information]
  • Standfield, L., Weston, A., Barraclough, H., Van Kooten, M., Pavlakis, N. (2011). Histology as a treatment effect modifier in advanced non-small cell lung cancer: A systematic review of the evidence. Respirology, 16(8), 1210-1220. [More Information]
  • Khasraw, M., Lassman, A., Wheeler, H., Pavlakis, N. (2010). Anti-angiogenic therapy for high grade glioma (Protocol). Cochrane Database of Systematic Reviews, 2, 1-9.
  • Stewart, T., Pavlakis, N., Ward, M. (2010). Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Internal Medicine Journal, 40(4), 303-307. [More Information]
  • Asmis, T., Powell, E., Karapetis, C., Jonker, D., Tu, D., Jeffery, M., Pavlakis, N., Gibbs, P., Zhu, L., Dueck, D., et al (2010). Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Annals of Oncology, 22(1), 118-126. [More Information]
  • Tebbutt, N., Karapetis, C., Segelov, E., Pavlakis, N., Cunningham, D., Sobrero, A., Haller, D., Shapiro, J. (2010). Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. Clinical Colorectal Cancer, 9(1), 8-14. [More Information]
  • Kao, S., Pavlakis, N., Harvie, R., Vardy, J., Boyer, M., van Zandwijk, N., Clarke, S. (2010). High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clinical Cancer Research, 16(23), 5805-5813. [More Information]
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Beale, P., Pavlakis, N., Kothe, E., Lam, L., Rosenthal, D. (2010). Impact of Medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial. Annals of Oncology, 21(3), 608-614. [More Information]
  • Khasraw, M., Pavlakis, N., McCowatt, S., Underhill, C., Begbie, S., De Souza, P., Boyce, A., Parnis, F., Lim, V., Harvie, R., et al (2010). Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Annals of Oncology, 21(6), 1302-1307. [More Information]
  • Khasraw, M., Townsend, A., Price, T., Hart, J., Bell, D., Pavlakis, N. (2010). Objective radiological disease control with Sandostatin monotherapy in metastatic neuroendocrine tumours. Internal Medicine Journal, 40(6), 453-458. [More Information]
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Tattersall, M., Boyer, M., Beale, P., Vardy, J., Pavlakis, N., Larke, L. (2010). Patient-Doctor Communication: Use of Complementary and Alternative Medicine by Adult Patients with Cancer. Journal of the Society for Integrative Oncology, 8(2), 56-64. [More Information]
  • Crino, L., Dansin, E., Garrido, P., Griesinger, F., Laskin, J., Pavlakis, N., Stroiakovski, D., Thatcher, N., Tsai, C., Wu, Y., et al (2010). Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncology, 11(8), 733-740. [More Information]
  • Evans, K., Richardson, M., Pavlakis, N., Morris, D., Liauw, W., Bester, L. (2010). Survival Outcomes of a Salvage Patient Population after Radioembolization of Hepatic Metastases with Yttrium-90 Microspheres. Journal of Vascular and Interventional Radiology, 21(10), 1521-1526. [More Information]
  • Oh, B., Butow, P., Mullan, B., Beale, P., Pavlakis, N., Rosenthal, D., Clarke, S. (2010). The use and perceived benefits resulting from the use of complementary and alternative medicine by cancer patients in Australia. Asia-Pacific Journal of Clinical Oncology, 6(4), 342-349. [More Information]
  • Khasraw, M., Atkinson, C., Van der Saag, D., Pavlakis, N., Guminski, A. (2009). Cardiac toxicity from sunitinib: Do we need to be more vigilant? Asia-Pacific Journal of Clinical Oncology, 5(4), 217-218. [More Information]
  • Au, H., Karapetis, C., O'Callaghan, C., Tu, D., Moore, M., Zalcberg, J., Kennecke, H., Shapiro, J., Koski, S., Pavlakis, N., et al (2009). Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. Journal of Clinical Oncology, 27(11), 1822-1828. [More Information]
  • Zhao, L., Lee, B., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Kaplan, W., Breit, S., et al (2009). Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Research, 69(19), 7696-7703. [More Information]
  • Khasraw, M., Gill, A., Harrington, T., Pavlakis, N., Modlin, I. (2009). Management of Advanced Neuroendocrine Tumors With Hepatic Metastasis. Journal of Clinical Gastroenterology, 43(9), 838-47. [More Information]
  • Krieger, L., Pavlakis, N. (2009). Phase III trials of neo-adjuvant chemotherapy in Stage IIIA non-small cell lung cancer. Does size matter? Asia-Pacific Journal of Clinical Oncology, 5(2), 73-75.
  • Van Hazel, G., Pavlakis, N., Goldstein, D., Olver, I., Tapner, M., Price, D., Bower, G., Briggs, G., Rossleigh, M., Taylor, D., George, J. (2009). Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy. Journal of Clinical Oncology, 27(25), 4089-4095. [More Information]
  • Herbertson, R., Karapetis, C., Price, T., Tebbutt, N., Pavlakis, N. (2008). Epidermal growth factor receptor (EGF-R) inhibitors for metastatic colorectal cancer. Cochrane Database of Systematic Reviews, 2, CD007047.
  • Krieger, L., Pavlakis, N. (2008). Evolution of biological therapies in non-small cell lung cancer. Cancer Forum, 32, 147-150.
  • Gananadha, S., Hazebroek, E., Leibman, S., Berry, H., Osgood, L., Shon, I., Pavlakis, N., Marx, G., Smith, G. (2008). The utility of FDG-PET in the preoperative staging of esophageal cancer. Diseases of the Esophagus, 21(5), 389-394. [More Information]
  • Stordal, B., Pavlakis, N., Davey, R. (2007). A systematic review of platinum and taxane resistance from bench to clinic: An inverse relationship. Cancer Treatment Reviews, 33(8), 688-703. [More Information]
  • Stordal, B., Pavlakis, N., Davey, R. (2007). Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treatment Reviews, 33, 347-357. [More Information]
  • Desai, J., Gurney, H., Pavlakis, N., McArthur, G., Davis, I. (2007). Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management. Asia-Pacific Journal of Clinical Oncology, 3(4), 167-176. [More Information]
  • Pavlakis, N., Patel, D., Stockler, M. (2006). Biphosphonates in early prostate cancer. Cochrane Database of Systematic Reviews, 4, CD006249.
  • Pavlakis, N. (2006). Drug treatment of renal cancer. Australian Prescriber, 29, 159-161.
  • Pavlakis, N., Vogelzang, N. (2006). Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma. Expert opinion on biological therapy, 6(4), 391-399. [More Information]
  • Pavlakis, N., Schmidt, R., Stockler, M. (2005). Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews, (3), CD003474. [More Information]
  • Pavlakis, N., Stockler, M. (2003). Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews, 11.
  • Pavlakis, N., Stockler, M. (2002). Bisphosphonates in breast cancer. Cochrane Database of Systematic Reviews, , 1-28.
  • Pavlakis, N., Laurent, R. (2001). Role of the observed long case in postgraduate medical training. Internal Medicine Journal, 31, 523-528.

2014

  • Wang, F., Gill, A., Neale, M., Puttaswamy, V., Gananadha, S., Pavlakis, N., Clarke, S., Hugh, T., Samra, J. (2014). Adverse tumor biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma. Annals of Surgical Oncology, 21(6), 1937-1947. [More Information]
  • Lin, H., Castillo, L., Mahon, K., Chiam, K., Lee, B., Nguyen, Q., Boyer, M., Stockler, M., Pavlakis, N., Marx, G., Gurney, H., Horvath, L., et al (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. British Journal of Cancer, 110(10), 2462-2471. [More Information]
  • Hudson, A., Weir, C., Moon, E., Harvie, R., Klebe, S., Clarke, S., Pavlakis, N., Howell, V. (2014). Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma. Scientific Reports, 4, 6152. [More Information]
  • Cooper, W., Fox, S., O'Toole, S., Morey, A., Frances, G., Pavlakis, N., OBrien, K., Dettrick, A., Leong, T., et al (2014). National Working Group Meeting on ALK diagnostics in lung cancer. Asia-Pacific Journal of Clinical Oncology, 12(SUPPL. 2), 11-17. [More Information]
  • Paik, J., Toon, C., Benn, D., High, H., Hasovitz, C., Pavlakis, N., Clifton-Bligh, R., Gill, A. (2014). Renal Carcinoma Associated With Succinate Dehydrogenase B Mutation: A New and Unique Subtype of Renal Carcinoma. Journal of Clinical Oncology, 32(6), e10-e13. [More Information]
  • Weir, C., Hudson, A., Moon, E., Ross, A., Alexander, M., Peters, L., Langova, V., Clarke, S., Pavlakis, N., Davey, R., Howell, V. (2014). Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines. Cancer Immunology Research, 2(5), 469-479. [More Information]
  • Segelov, E., Chan, D., Shapiro, J., Price, T., Karapetis, C., Tebbutt, N., Pavlakis, N. (2014). The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. British Journal of Cancer, 111(6), 1122-1131. [More Information]

2013

  • Nowak, A., Brown, C., Millward, M., Creaney, J., Byrne, M., Hughes, B., Kremmidiotis, G., Bibby, D., Leske, A., Mitchell, P., Pavlakis, N., Stockler, M., et al (2013). A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer, 81(3), 422-427. [More Information]
  • Vickers, M., Karapetis, C., Tu, D., O'Callaghan, C., Price, T., Tebbutt, N., van Hazel, G., Shapiro, J., Pavlakis, N., Gibbs, P., Simes, R., et al (2013). Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Annals of Oncology, 24(4), 953-960. [More Information]
  • Price, T., Segelov, E., Burge, M., Haller, D., Ackland, S., Tebbutt, N., Karapetis, C., Pavlakis, N., Sobrero, A., Cunningham, D., et al (2013). Current opinion on optimal treatment for colorectal cancer. Expert Review of Anticancer Therapy, 13(5), 597-611. [More Information]
  • Tebbutt, N., Parry, M., Zannino, D., Strickland, A., van Hazel, G., Pavlakis, N., Ganju, V., Mellor, D., Dobrovic, A., Gebski, V. (2013). Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. British Journal of Cancer, 108(4), 771-774. [More Information]
  • Hasovits, C., Pavlakis, N. (2013). EGFR-Targeted therapy and resistance. Cancer Forum, 37(2), 166-170.
  • Kao, S., Vardy, J., Harvie, R., Chatfield, M., van Zandwijk, N., Clarke, S., Pavlakis, N. (2013). Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Supportive Care in Cancer, 21(3), 697-705. [More Information]
  • Pavlakis, N., Solomon, B. (2013). Lung cancer beyond 2013: Many different diseases. Cancer Forum, 37(2), 143-145.
  • Clarke, S., Karapetis, C., Gibbs, P., Pavlakis, N., Desai, J., Michael, M., Tebbutt, N., Price, T., Tabernero, J. (2013). Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors. Critical Reviews in Oncology / Hematology (online), 85(2), 121-135. [More Information]
  • Hasovits, C., Pavlakis, N., Howell, V., Gill, A., Clarke, S. (2013). Resistance to EGFR targeted antibodies - expansion of clones present from the start of treatment. The more things change, the more they stay the same (Plus ca change, plus ca ne change pas!). Translational Gastrointestinal Cancer, 28(1), 44-46. [More Information]
  • Buikhuisen, W., Burgers, J., Vincent, A., Korse, C., van Klaveren, R., Schramel, F., Pavlakis, N., Nowak, A., Custers, F., Schouwink, J., et al (2013). Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. The Lancet Oncology, 14(6), 543-551. [More Information]
  • Cummins, M., Pavlakis, N. (2013). The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events. Therapeutic Advances in Medical Oncology, 5(5), 286-300.
  • Kao, S., Vardy, J., Chatfield, M., Corte, P., Pavlakis, N., Clarke, C., van Zandwijk, N., Clarke, S. (2013). Validation of Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Analysis of Data from Patients Seeking Compensation from the New South Wales Dust Diseases Board. Clinical Lung Cancer, 14(1), 70-77. [More Information]

2012

  • Michael, M., Pavlakis, N., Clingan, P., de Boer, R., Johnston, M., Clarke, S. (2012). A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer. Oncology reports, 28(3), 763-767. [More Information]
  • Wong, M., Stockler, M., Pavlakis, N. (2012). Bisphosphonates and other bone agents for breast cancer (Review). The Cochrane Library Chichester UK: John Wiley and Sons Ltd, 2, 1-136. [More Information]
  • Weickhardt, A., Price, T., Chong, G., Gebski, V., Pavlakis, N., Johns, T., Azad, A., Skrinos, E., Fluck, K., Dobrovic, A., et al (2012). Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. Journal of Clinical Oncology, 30(13), 1505-1512. [More Information]
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Beale, P., Pavlakis, N., Lee, M., Rosenthal, D., Larkey, L., Vardy, J. (2012). Effect of Medical Qigong on Cognitive function, Quality of Life and a Biomarker of Inflammation in Cancer Patients: A Randomized Controlled Trial. Supportive Care in Cancer, 20(6), 1235-1242. [More Information]
  • Boyer, M., Horwood, K., Pavlakis, N., de Souza, P., Millward, M., Stein, B., Johnston, M., Abell, F., Rischin, D. (2012). Efficacy of erlotinib in patients with advanced Non-small-cell Lung Cancer (NSCLC): Analysis of the Australian subpopulation of the TRUST study. Asia-Pacific Journal of Clinical Oncology, 8(3), 248-254. [More Information]
  • Price, T., Shapiro, J., Segelov, E., Karapetis, C., Pavlakis, N., Van Cutsem, E., Shah, M., Kang, Y., Tebbutt, N. (2012). Management of advanced gastric cancer. Expert Review of Gastroenterology and Hepatology, 6(2), 199-209. [More Information]
  • Biankin, A., Waddell, N., Kassahn, K., Gingras, M., Muthuswamy, L., Johns, A., Miller, D., Wilson, P., Patch, A., Wu, J., Gill, A., Kench, J., Pavlakis, N., Lam, V., Richardson, A., Samra, J., et al (2012). Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 491(7424), 399-405. [More Information]
  • Bester, L., Meteling, B., Pocock, N., Pavlakis, N., Chua, T., Saxena, A., Morris, D. (2012). Radioembolization versus Standard Care of Hepatic Metastases: Comparative Retrospective Cohort Study of Survival Outcomes and Adverse Events in Salvage Patients. Journal of Vascular and Interventional Radiology, 23(1), 96-105. [More Information]
  • Kao, S., Harvie, R., Paturi, F., Taylor, R., Davey, R., Abraham, R., Clarke, S., Marx, G., Cullen, M., Kerestes, Z., Pavlakis, N. (2012). The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer, 75(2), 248-254. [More Information]

2011

  • Paech, D., Weston, A., Pavlakis, N., Gill, A., Rajan, N., Barraclough, H., Fitzgerald, B., Van Kooten, M. (2011). A Systematic Review of the Interobserver Variability for Histology in the Differentiation between Squamous and Nonsquamos Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 6(1), 55-63. [More Information]
  • Asmis, T., Powell, E., Karapetis, C., Jonker, D., Tu, D., Jeffery, M., Pavlakis, N., Gibbs, P., Zhu, L., Dueck, D., et al (2011). Comorbidity, age and overall survival in cetuximabtreated patients with advanced colorectal cancer (ACRC)-results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Annals of Oncology, 22, 118-126. [More Information]
  • Standfield, L., Weston, A., Barraclough, H., Van Kooten, M., Pavlakis, N. (2011). Histology as a treatment effect modifier in advanced non-small cell lung cancer: A systematic review of the evidence. Respirology, 16(8), 1210-1220. [More Information]

2010

  • Khasraw, M., Lassman, A., Wheeler, H., Pavlakis, N. (2010). Anti-angiogenic therapy for high grade glioma (Protocol). Cochrane Database of Systematic Reviews, 2, 1-9.
  • Stewart, T., Pavlakis, N., Ward, M. (2010). Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina. Internal Medicine Journal, 40(4), 303-307. [More Information]
  • Asmis, T., Powell, E., Karapetis, C., Jonker, D., Tu, D., Jeffery, M., Pavlakis, N., Gibbs, P., Zhu, L., Dueck, D., et al (2010). Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)--results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Annals of Oncology, 22(1), 118-126. [More Information]
  • Tebbutt, N., Karapetis, C., Segelov, E., Pavlakis, N., Cunningham, D., Sobrero, A., Haller, D., Shapiro, J. (2010). Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. Clinical Colorectal Cancer, 9(1), 8-14. [More Information]
  • Kao, S., Pavlakis, N., Harvie, R., Vardy, J., Boyer, M., van Zandwijk, N., Clarke, S. (2010). High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clinical Cancer Research, 16(23), 5805-5813. [More Information]
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Beale, P., Pavlakis, N., Kothe, E., Lam, L., Rosenthal, D. (2010). Impact of Medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial. Annals of Oncology, 21(3), 608-614. [More Information]
  • Khasraw, M., Pavlakis, N., McCowatt, S., Underhill, C., Begbie, S., De Souza, P., Boyce, A., Parnis, F., Lim, V., Harvie, R., et al (2010). Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Annals of Oncology, 21(6), 1302-1307. [More Information]
  • Khasraw, M., Townsend, A., Price, T., Hart, J., Bell, D., Pavlakis, N. (2010). Objective radiological disease control with Sandostatin monotherapy in metastatic neuroendocrine tumours. Internal Medicine Journal, 40(6), 453-458. [More Information]
  • Oh, B., Butow, P., Mullan, B., Clarke, S., Tattersall, M., Boyer, M., Beale, P., Vardy, J., Pavlakis, N., Larke, L. (2010). Patient-Doctor Communication: Use of Complementary and Alternative Medicine by Adult Patients with Cancer. Journal of the Society for Integrative Oncology, 8(2), 56-64. [More Information]
  • Crino, L., Dansin, E., Garrido, P., Griesinger, F., Laskin, J., Pavlakis, N., Stroiakovski, D., Thatcher, N., Tsai, C., Wu, Y., et al (2010). Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncology, 11(8), 733-740. [More Information]
  • Evans, K., Richardson, M., Pavlakis, N., Morris, D., Liauw, W., Bester, L. (2010). Survival Outcomes of a Salvage Patient Population after Radioembolization of Hepatic Metastases with Yttrium-90 Microspheres. Journal of Vascular and Interventional Radiology, 21(10), 1521-1526. [More Information]
  • Oh, B., Butow, P., Mullan, B., Beale, P., Pavlakis, N., Rosenthal, D., Clarke, S. (2010). The use and perceived benefits resulting from the use of complementary and alternative medicine by cancer patients in Australia. Asia-Pacific Journal of Clinical Oncology, 6(4), 342-349. [More Information]

2009

  • Stordal, B., Pavlakis, N., Davey, R. (2009). A systematic alalysis of oxaliplatin or paclitaxel salvage chemotherapy. In Andrea Bonetti, Roberto Leone,Franco M Muggia, Stephen B Howell (Eds.), Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications, (pp. 225-230). US: Humana Press.
  • Khasraw, M., Atkinson, C., Van der Saag, D., Pavlakis, N., Guminski, A. (2009). Cardiac toxicity from sunitinib: Do we need to be more vigilant? Asia-Pacific Journal of Clinical Oncology, 5(4), 217-218. [More Information]
  • Au, H., Karapetis, C., O'Callaghan, C., Tu, D., Moore, M., Zalcberg, J., Kennecke, H., Shapiro, J., Koski, S., Pavlakis, N., et al (2009). Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. Journal of Clinical Oncology, 27(11), 1822-1828. [More Information]
  • Zhao, L., Lee, B., Brown, D., Molloy, M., Marx, G., Pavlakis, N., Boyer, M., Stockler, M., Kaplan, W., Breit, S., et al (2009). Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Research, 69(19), 7696-7703. [More Information]
  • Khasraw, M., Gill, A., Harrington, T., Pavlakis, N., Modlin, I. (2009). Management of Advanced Neuroendocrine Tumors With Hepatic Metastasis. Journal of Clinical Gastroenterology, 43(9), 838-47. [More Information]
  • Krieger, L., Pavlakis, N. (2009). Phase III trials of neo-adjuvant chemotherapy in Stage IIIA non-small cell lung cancer. Does size matter? Asia-Pacific Journal of Clinical Oncology, 5(2), 73-75.
  • Van Hazel, G., Pavlakis, N., Goldstein, D., Olver, I., Tapner, M., Price, D., Bower, G., Briggs, G., Rossleigh, M., Taylor, D., George, J. (2009). Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy. Journal of Clinical Oncology, 27(25), 4089-4095. [More Information]

2008

  • Nowak, A., Feigen, M., Pavlakis, N. (2008). Clinical trials in mesothelioma: Australasia? In A Baldi (Eds.), Mesothelioma from Bench Side to Clinic, (pp. 501-519). United States: Nova Science Publishers.
  • Herbertson, R., Karapetis, C., Price, T., Tebbutt, N., Pavlakis, N. (2008). Epidermal growth factor receptor (EGF-R) inhibitors for metastatic colorectal cancer. Cochrane Database of Systematic Reviews, 2, CD007047.
  • Krieger, L., Pavlakis, N. (2008). Evolution of biological therapies in non-small cell lung cancer. Cancer Forum, 32, 147-150.
  • Gananadha, S., Hazebroek, E., Leibman, S., Berry, H., Osgood, L., Shon, I., Pavlakis, N., Marx, G., Smith, G. (2008). The utility of FDG-PET in the preoperative staging of esophageal cancer. Diseases of the Esophagus, 21(5), 389-394. [More Information]

2007

  • Stordal, B., Pavlakis, N., Davey, R. (2007). A systematic review of platinum and taxane resistance from bench to clinic: An inverse relationship. Cancer Treatment Reviews, 33(8), 688-703. [More Information]
  • Stordal, B., Pavlakis, N., Davey, R. (2007). Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treatment Reviews, 33, 347-357. [More Information]
  • Desai, J., Gurney, H., Pavlakis, N., McArthur, G., Davis, I. (2007). Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management. Asia-Pacific Journal of Clinical Oncology, 3(4), 167-176. [More Information]

2006

  • Pavlakis, N., Patel, D., Stockler, M. (2006). Biphosphonates in early prostate cancer. Cochrane Database of Systematic Reviews, 4, CD006249.
  • Pavlakis, N. (2006). Drug treatment of renal cancer. Australian Prescriber, 29, 159-161.
  • Pavlakis, N., Vogelzang, N. (2006). Ranpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma. Expert opinion on biological therapy, 6(4), 391-399. [More Information]

2005

  • Pavlakis, N., Schmidt, R., Stockler, M. (2005). Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews, (3), CD003474. [More Information]
  • Pavlakis, N., Vogelzang, N. (2005). Second-line chemotherapy. In Harvey I Pass, Nicholas J Vogelzang, Michele Carbone (Eds.), Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies, (pp. 607-615). United States of America: Springer.

2003

  • Pavlakis, N., Stockler, M. (2003). Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews, 11.

2002

  • Pavlakis, N., Stockler, M. (2002). Bisphosphonates in breast cancer. Cochrane Database of Systematic Reviews, , 1-28.

2001

  • Pavlakis, N., Laurent, R. (2001). Role of the observed long case in postgraduate medical training. Internal Medicine Journal, 31, 523-528.

To update your profile click here. For support on your academic profile contact .